Substituted bridged urea analogs as sirtuin modulators
US-2015152108-A1 · Jun 4, 2015 · US
Substituted bridged urea analogs as sirtuin modulators
US9765075B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9765075-B2 |
| Application number | US-201414891158-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 13, 2014 |
| Priority date | May 13, 2013 |
| Publication date | Sep 19, 2017 |
| Grant date | Sep 19, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
First claim
Opening claim text (preview).
We claim: 1. A compound which is: or a pharmaceutically acceptable salt thereof. 2. A compound which is: 3. A pharmaceutical composition comprising a compound of claim 1 or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient, carrier or diluent. 4. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable excipient, carrier or diluent.
Assignees
Inventors
Classifications
Bridged systems · CPC title
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
having two nitrogen atoms, e.g. dilazep · CPC title
- C07D471/18Primary
Bridged systems · CPC title
not condensed and containing further heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9765075B2 cover?
- Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular diseas…
- Who is the assignee on this patent?
- Glaxosmithkline Llc
- What technology area does this patent fall under?
- Primary CPC classification C07D471/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).